P. Talaga
(Associate Director, Discovery Technologies, **UCB Pharma**)

Professional address:
UCB Pharma
Chemin du Foriest
B-1420 Braine-l'Alleud
Belgium
Tel. (32.2) 386.27.27
Fax. (32.2) 386.27.04
E-mail : patrice.talaga@ucb-group.com

15 years of experience in Pharmaceutical Industry

Major current responsibilities:

- Global Chemical Outsourcing: academic & CRO (Medicinal Chemistry, Combinatorial chemistry, Custom Synthesis, compound acquisition...).
- Combinatorial Chemistry Global In/Out
- Compound Management Global
- High Throughput Screening Global

Previously: Research Project(s) management (CNS area e.g. Neurodegeneration, epilepsy, etc…). Biological targets discovery related to CNS (neurodegenerative diseases, Parkinson's…) and immuno-allergy diseases.

Education

- **1995**: **Master in Drug Design/Molecular Pharmacology** (Ecole Nationale Supérieure de Chimie de Lille, Institut de Chimie Pharmaceutique de l'Université du Droit et de la Santé de Lille, France).
- **1989**: **Ph.D. in Organic Chemistry** (Supervisor: Prof. C. Benezra, Université Louis Pasteur, Strasbourg - France). Thesis related to the synthesis and biological testing of Allergen-(non)Peptide conjugates for the treatment of Contact Dermatitis.
- **1985**: **Master in Biochemistry** (Université Louis Pasteur, Strasbourg - France).

Selected publications

Discovery of Seletracetam: A new pyrrolidone derivative with potent antiepileptic properties and high tolerability in rodent models of Epilepsy. Kenda, B.; Matagne, A.; Talaga, P.; Michel, P. *Abstracts of Papers American Chemical Society, (MAR 26 2006) Vol. 231, pp. 200-MEDI.*

Compounds comprising an oxazoline or thiazoline moiety, processes of making them, and their uses. S. Celanire, P. Talaga, R. Leurs, F. Denonne, H. Timmerman, F. Lebon. *Patent application WO 2006/103057*, **2006**.

Potent anti-muscarinic activity in a novel series of quinuclidine derivatives. J.P. Starck, P. Talaga, L. Quere, P. Collart, B. Cristophe, P. Lo Brutto, S. Jadot, S. Chimmanamada, M. Zanda, A. Wagner, C. Mioskowski, R. Massingham, M. Guyaux. *Bioorg. Med. Chem. Lett*. **2006**, *16*, 373-377.

Histamine H3 receptor antagonists reach out for the clinic. S. Celanire, S. Wijtmans, P. Talaga, R. Leurs, IJ. De Esch. *Drug Discovery Today* **2005**, *10*, 1613-1627.

In vitro properties of 5-(benzylsulfonyl)-4-bromo-2-methyl-3(2H)-pyridazinone: A novel permeability transition pore inhibitor. B. Fuks; P. Talaga; C. Huart; J.P. Hénichart; K. Bertrand; R. Grimée; G. Lorent. *Eur. J. Pharmacol.* **2005**, *519*, 24-30.

Inhibitors of beta-amyloid aggregation: still an issue of structure and function? Talaga P. *Drug Discovery Today: Therapeutic Strategies.* **2004**, *1*, 7-12.

Dual Acting Antihistaminergic Agents. Scannel R.T.; Differding E.; Talaga P. *Mini-Reviews in Medicinal Chemistry*. **2004**, *4*, 941-951.

Identification of 4-(1H-Imidazol-4(5)-ylmethyl)pyridine (Immethridine) as a Novel, Potent, and Highly Selective Histamine H3 Receptor Agonist. Kitbunnadaj, R.; Zuiderveld O.P.; Christophe B.; Hulcher S.; Menge W.M.P.B.; Gelens E.; Snip E.; Bakker R.A.; Celanire S.; Gillard M.; Talaga P.; Timmerman H.; Leurs R. *J. Med. Chem.* **2004**, *47*, 2414-2417.

Compound decomposition: a new drug discovery tool? Talaga P. *Drug Discovery Today*, **2004**, *9*, 51-53.

Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity. Kenda B.; Matagne A.; Talaga P.; Pasau P.; Differding E.; Lallemand B.; Frycia A.; Moureau F.; Klitgaard H.; Gillard M.; Fuks B.; Michel P. *J. Med. Chem*., **2004**, *47*, 530-549.

Chemical Compounds with dual activity, processes for their preparation and pharmaceutical compositions. Provins L.; Van Keulen B.J.; Surtees J.; Talaga P.; Christophe B. *Patent application WO 03/087064 A1*, **2003**.

Quinuclidine derivatives, processes for preparing them and their uses as M2 and/or M3 muscarinic receptor inhibitors. Guyaux M.; Dinesh C.; Mioskowski C.; Quere L.; Starck J.P.; Talaga P.; Wagner A.; Zanda M. *Patent application WO 03/033495 A1*, **2003**.

The Plasma Membrane: A Target and Hurdle for the Development of Anti-Aβ Drugs? P. Talaga, L. Quéré. *Current Drug Targets – CNS & Neurological Disorders*, **2002**, *1*, 565-572.

Dual NK1 Antagonists – Serotonin Reuptake Inhibitors as Potential Antidepressants. Part 2: SAR and Activity of Benzyloxyphenetyl Piperazine Derivatives. T. Ryckmans, O. Berton, R. Grimée, T. Kogej, Y. Lamberty, P. Pasau, P. Talaga & C. Genicot. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 3195-3198.

Synthesis of newer KEPPRA™ analogs. Archen L.; Differding E.; Evrard Y.; Frycia A.; Gotteaux C.; Fuks B.; Gillard M.; Kenda B.; Klitgaard H.; Lallemand B.; Matagne A.; Michel P.; Pasau P.; Perl F.; Talaga P.; Van Thuyne M. *Drugs Fut* **2002**, *27*(Suppl.A): XVIIth Int. Symp. On Medicinal Chemistry, 358.

A New Series of M3 Muscarinic Antagonists based on the 4-Amino-piperidine Scaffold. O. Diouf, S. Gadeau, F. Chellé, M. Gelbcke, P. Talaga, B. Christophe, M. Gillard, R. Massingham, M. Guyaux. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 2535-2539.

First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepresssants. T. Ryckmans, L. Balançon, O. Berton, C. Genicot, Y. Lamberty, B. Lallemand, P. Pasau, N. Pirlot, L. Quere, P. Talaga. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 261-264.

2-Oxo-1-Pyrrolidine derivatives, processes for preparing them and their uses. E. Differding, B. Kenda, B. Lallemand, A. Matagne, P. Michel, P. Pasau, P. Talaga. *Patent application WO 01/62726 A2*, **2001**.

β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease: Dream or Reality? P. Talaga. *Mini Reviews in Medicinal Chemistry*, **2001**, *1*, 175-186.

Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. A. Bocquet, G. Lorent, B. Fuks, R. Grimée, P. Talaga, J. Daliers, H. Klitgaard. *Eur. J. Pharmacol.* **2001**, *415*, 173-180.

Pharmacological Evaluation of a Diarylmethylene-Piperidine Derivative: A New Potent Atypical Antipsychotic? P. Talaga, A. Matagne, H. Klitgaard. *Bioorg. Med. Chem. Lett*. **2001**, *11*, 1313-1316.